AtriCure EBITDA Margin 2012-2025 | ATRC
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for AtriCure (ATRC) over the last 10 years. The current EBITDA margin for AtriCure as of September 30, 2025 is .
| AtriCure EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-09-30 | $0.52B | $-0.01B | -1.35% |
| 2025-06-30 | $0.50B | $-0.01B | -2.80% |
| 2025-03-31 | $0.48B | $-0.02B | -3.33% |
| 2024-12-31 | $0.47B | $-0.02B | -4.52% |
| 2024-09-30 | $0.45B | $-0.02B | -3.35% |
| 2024-06-30 | $0.43B | $-0.02B | -3.95% |
| 2024-03-31 | $0.42B | $-0.01B | -3.37% |
| 2023-12-31 | $0.40B | $-0.01B | -2.76% |
| 2023-09-30 | $0.38B | $-0.01B | -2.11% |
| 2023-06-30 | $0.37B | $-0.01B | -3.01% |
| 2023-03-31 | $0.35B | $-0.02B | -6.02% |
| 2022-12-31 | $0.33B | $-0.03B | -8.76% |
| 2022-09-30 | $0.32B | $-0.04B | -11.71% |
| 2022-06-30 | $0.30B | $0.16B | 51.16% |
| 2022-03-31 | $0.29B | $0.15B | 52.94% |
| 2021-12-31 | $0.27B | $0.15B | 55.31% |
| 2021-09-30 | $0.26B | $0.15B | 56.20% |
| 2021-06-30 | $0.24B | $-0.04B | -16.87% |
| 2021-03-31 | $0.21B | $-0.03B | -15.96% |
| 2020-12-31 | $0.21B | $-0.03B | -16.43% |
| 2020-09-30 | $0.21B | $-0.03B | -15.24% |
| 2020-06-30 | $0.21B | $-0.04B | -17.45% |
| 2020-03-31 | $0.23B | $-0.03B | -14.78% |
| 2019-12-31 | $0.23B | $-0.02B | -10.39% |
| 2019-09-30 | $0.22B | $-0.01B | -4.93% |
| 2019-06-30 | $0.22B | $-0.01B | -4.17% |
| 2019-03-31 | $0.21B | $0.00B | -1.91% |
| 2018-12-31 | $0.20B | $-0.01B | -3.96% |
| 2018-09-30 | $0.20B | $-0.01B | -4.10% |
| 2018-06-30 | $0.19B | $-0.01B | -4.81% |
| 2018-03-31 | $0.18B | $-0.02B | -8.89% |
| 2017-12-31 | $0.17B | $-0.02B | -9.20% |
| 2017-09-30 | $0.17B | $-0.02B | -12.43% |
| 2017-06-30 | $0.17B | $-0.02B | -12.12% |
| 2017-03-31 | $0.16B | $-0.02B | -13.13% |
| 2016-12-31 | $0.16B | $-0.02B | -13.55% |
| 2016-09-30 | $0.15B | $-0.02B | -16.00% |
| 2016-06-30 | $0.14B | $-0.02B | -16.78% |
| 2016-03-31 | $0.14B | $-0.02B | -16.18% |
| 2015-12-31 | $0.13B | $-0.02B | -14.62% |
| 2015-09-30 | $0.12B | $-0.01B | -11.38% |
| 2015-06-30 | $0.12B | $-0.01B | -7.56% |
| 2015-03-31 | $0.11B | $-0.01B | -7.08% |
| 2014-12-31 | $0.11B | $-0.01B | -10.19% |
| 2014-09-30 | $0.10B | $-0.01B | -11.88% |
| 2014-06-30 | $0.09B | $-0.02B | -15.96% |
| 2014-03-31 | $0.09B | $-0.01B | -16.09% |
| 2013-12-31 | $0.08B | $-0.01B | -9.88% |
| 2013-09-30 | $0.08B | $-0.01B | -6.49% |
| 2013-06-30 | $0.07B | $-0.01B | -6.85% |
| 2013-03-31 | $0.07B | $-0.01B | -7.04% |
| 2012-12-31 | $0.07B | $-0.01B | -7.25% |
| 2012-09-30 | $0.07B | $-0.01B | -7.35% |
| 2012-06-30 | $0.07B | $0.00B | -5.97% |
| 2012-03-31 | $0.07B | $0.00B | -4.55% |
| 2011-12-31 | $0.07B | $0.00B | -3.08% |
| 2011-09-30 | $0.06B | $0.00B | -1.56% |
| 2011-06-30 | $0.06B | 0 | 0.00% |
| 2011-03-31 | $0.06B | 0 | 0.00% |
| 2010-12-31 | $0.06B | $0.00B | -1.72% |
| 2010-09-30 | $0.06B | $0.00B | -3.57% |
| 2010-06-30 | $0.06B | $-0.01B | -10.91% |
| 2010-03-31 | $0.06B | $-0.01B | -10.91% |
| 2009-12-31 | $0.06B | $-0.01B | -10.91% |
| 2009-09-30 | $0.05B | $-0.01B | -15.09% |
| 2009-06-30 | $0.06B | $-0.01B | -9.09% |
| 2009-03-31 | $0.06B | $-0.01B | -10.71% |
| 2008-12-31 | $0.06B | $-0.01B | -14.29% |
| 2008-09-30 | $0.06B | $-0.01B | -10.53% |
| 2008-06-30 | $0.05B | $-0.01B | -12.96% |
| 2008-03-31 | $0.05B | $-0.01B | -17.65% |
| 2007-12-31 | $0.05B | $-0.01B | -20.83% |
| 2007-09-30 | $0.05B | $-0.01B | -28.26% |
| 2007-06-30 | $0.04B | $-0.01B | -32.56% |
| 2007-03-31 | $0.04B | $-0.01B | -34.15% |
| 2006-12-31 | $0.04B | $-0.01B | -33.33% |
| 2006-09-30 | $0.04B | $-0.01B | -35.14% |
| 2006-06-30 | $0.04B | $-0.01B | -37.14% |
| 2006-03-31 | $0.03B | $-0.01B | -33.33% |
| 2005-12-31 | $0.03B | $-0.01B | -29.03% |
| 2005-09-30 | $0.03B | $-0.01B | -23.08% |
| 2005-06-30 | $0.02B | $0.00B | -12.50% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $1.845B | $0.465B |
| AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. | |||